| DC22582 |
AS601245
Featured
|
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties. |
|
| DC23005 |
SC 57461
Featured
|
A potent and selective inhibitor of LTA4 hydrolase (LTA4H) with IC50/Ki of 5 nM/23 nM. |
|
| DC24091 |
TH-287 hydrochloride
Featured
|
TH287 hydrochloride is a potent and selective inhibitor of MTH1, with an IC50 of 0.8 nM. TH287 hydrochloride is highly selective towards MTH1, with no relevant inhibition of MTH2, NUDT5, NUDT12, NUDT14, NUDT16, dCTPase, dUTPase and ITPA at 100 μM. TH287 hydrochloride could act as a chemotherapeutic agent for cancer research. |
|
| DC21767 |
AG-1296
Featured
|
A potent and selective inhibitor of PDGFR with IC50 of about 0.4 uM both in vitro and in cells. |
|
| DC24066 |
CYT387 mesylate
Featured
|
A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
|
| DC24067 |
CYT387 sulfate salt
Featured
|
A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM. |
|
| DC22655 |
UNC-1679
Featured
|
UNC-1679 (UNC1679) is a potent and selective small molecule chemical probe of a methyl-lysine reader protein L3MBTL3 with Ki of 0.35 uM. |
|
| DC21581 |
RO 5203648
Featured
|
A potent and selective TAAR1 partial agonist with Ki of 0.5, 1.0, 6.8 and 2.6 nM for mouse, rat, human and monkey TAAR1, respectively. |
|
| DC22380 |
NNC 55-0396 2HCl
Featured
|
NNC 55-0396, Mibefradil derivative, is a highly selective T-type calcium channel blocker; displays IC50 values of 6.8 and > 100 μM for inhibition of Cav3.1 T-type channels and HVA currents respectively in INS-1 cells. IC50 value: 6.8 nMTarget: Cav3.1 T-type channelNNC 55-0396 can be an essential tool in preventing human ovarian cancer cell proliferation as a result of its ability to inhibit the function of T-type Ca2+ channels. It is believed that NNC 55-0396 may functions by dissolving in or passing through the plasma membrane of cells. |
|
| DC22534 |
PI4KIIIbeta-IN-10
Featured
|
A potent and selective type III phosphatidylinositol 4-kinase (PI4KIIIβ) inhibitor with IC50 of 3.6 nM. |
|
| DC22913 |
WEB-2086
Featured
|
A potent and specific antagonist of platelet activating factor (PAF) receptor that inhibits PAF-induced human platelet and neutrophil aggregation in vitro with IC50 of 0.17 and 0.36 uM, respectively. |
|
| DC22375 |
RS-102895
Featured
|
RS102895 is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1. |
|
| DC24199 |
OSU-T315 (ILK-IN-1)
Featured
|
OSU-T315 (ILK-IN-1) is a potent and specific integrin-linked kinase (ILK) inhibitor which inhibits PDK2 function in the AKT pathway activation |
|
| DC22444 |
Leptomycin B
Featured
|
A potent and specific nuclear export inhibitor that binds to and inhibits CRM1 (XPO1). |
|
| DC22771 |
Proxalutamide
Featured
|
Proxalutamide (GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) for the potential treatment of COVID-19, prostate cancer, and breast cancer. |
|
| DC22443 |
Paxilline
Featured
|
A potent blocker of high-conductance Ca2+-activated K+ (BKCa, KCa1.1) channels that binds to the α-subunit of BKCa with Ki of 1.9 nM. |
|
| DC21833 |
DMP 543
Featured
|
A potent blocker of voltage-gated potassium channels Kv7 (KCNQ) that enhances ACh release from rat hippocampal slices in vitro with EC50 of 0.7 uM. |
_1.png)
|
| DC23905 |
Beaucage reagent
Featured
|
Beaucage reagent is a DNA cleavage reagent. |
|
| DC11797 |
PBD-150
Featured
|
A potent glutaminyl cyclase (QC) inhibitor with Ki of 60 nM. |
|
| DC23947 |
Indirubin-3'-monoxime
Featured
|
A potent GSK3β inhibitor with IC50 of 22 nM. |
|
| DC23991 |
Daclatasvir
Featured
|
Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. Nevertheless, and for unknown reasons, successful all-oral regimens of antiviral therapy in patients with chronic hepatitis C and cirrhosis is occasionally complicated by hepatic decompensation and may cause reactivation of hepatitis B in susceptible patients coinfected with the hepatitis B virus (HBV). |
.gif)
|
| DC22379 |
LDN-27219
Featured
|
A potent inhibitor of hTGase (Tissue transglutaminase) with IC50 of 0.8 uM. |
|
| DC23954 |
ISO-1
Featured
|
ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM. |
|
| DC22656 |
MM-401
Featured
|
A potent inhibitor of MLL1/WDR5 protein-protein interaction with IC50 of 0.9 nM. |
|
| DC22621 |
Elacridar hydrochloride
Featured
|
Elacridar Hcl (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.IC50 value:Target: P-glycoprotein In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects. |
|
| DC25028 |
AUDA
Featured
|
A potent inhibitor of sEH (soluble epoxide hydrolase) with IC50 of 18 nM and 69 nM for mouse sEH and human sEH, respectively. |
|
| DC7010 |
Cyclosporin H
Featured
|
A potent inhibitor of tumor promoting phorbol ester TPA/PMA and inhibitor of Ca2+/calmodulin dependent EF-2 phosphorylation |
|
| DC11753 |
BL-1249
Featured
|
BL-1249 is a nonsteroidal anti-inflammatory drug (NSAID) and a potassium channel activator. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM). BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively |
|
| DC23571 |
NS5806
Featured
|
NS5806 is a potent potassium current activator, increases KV4.3/KChIP2 peak current amplitudes with an EC50 of 5.3 μM. NS5806 slows KV4.3 and KV4.2 current dacay in channel complexes containing KChIP2[1]. |
|
| DC23951 |
Cevimeline hydrochloride
Featured
|
Cevimeline HCl is a cholinergic agonist that binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands, and increase tone of the smooth muscle in the GI and urinary tracts. |
|
